BioSpace News Archive

Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company’s proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

BioSkryb Genomics, a pioneer in comprehensive single cell multiomic research solutions, today announced the commercial launch of its ResolveOME™ Whole Genome and Transcriptome Amplification system and BaseJumper™ Bioinformatics Platform at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting.

Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report fourth quarter and fiscal year 2022 financial results on February 28, 2023, after the market close.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers

iCRYO, the fast-growing recovery and wellness brand, has announced their second annual Elevate Conference to take place in Houston this year.

BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York.

QIAGEN N.V. announced results for the fourth quarter and full-year 2022. Net sales for Q4 2022 declined 14% to $498 million from Q4 2021.

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022.